Tags

Type your tag names separated by a space and hit enter

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial.
J Allergy Clin Immunol. 2007 Jan; 119(1):192-8.JA

Abstract

BACKGROUND

The increase in allergic diseases is attributed to a relative lack of microbial stimulation of the infantile gut immune system. Probiotics, live health-promoting microbes, might offer such stimulation.

OBJECTIVE

We studied the effect of a mixture of 4 probiotic bacterial strains along with prebiotic galacto-oligosaccharides in preventing allergic diseases.

METHODS

We randomized 1223 pregnant women carrying high-risk children to use a probiotic preparation or a placebo for 2 to 4 weeks before delivery. Their infants received the same probiotics plus galacto-oligosaccharides (n = 461) or a placebo (n = 464) for 6 months. At 2 years, we evaluated the cumulative incidence of allergic diseases (food allergy, eczema, asthma, and allergic rhinitis) and IgE sensitization (positive skin prick test response or serum antigen-specific IgE level >0.7 kU/L). Fecal bacteria were analyzed during treatment and at age 2 years.

RESULTS

Probiotic treatment compared with placebo showed no effect on the cumulative incidence of allergic diseases but tended to reduce IgE-associated (atopic) diseases (odds ratio [OR], 0.71; 95% CI, 0.50-1.00; P = .052). Probiotic treatment reduced eczema (OR, 0.74; 95% CI, 0.55-0.98; P = .035) and atopic eczema (OR, 0.66; 95% CI, 0.46-0.95; P = .025). Lactobacilli and bifidobacteria more frequently (P < .001) colonized the guts of supplemented infants.

CONCLUSION

Probiotic treatment showed no effect on the incidence of all allergic diseases by age 2 years but significantly prevented eczema and especially atopic eczema. The results suggest an inverse association between atopic diseases and colonization of the gut by probiotics.

CLINICAL IMPLICATIONS

The prevention of atopic eczema in high-risk infants is possible by modulating the infant's gut microbiota with probiotics and prebiotics.

Links

Publisher Full Text
Aggregator Full Text
Aggregator Full Text

Authors+Show Affiliations

Kukkonen K
Skin and Allergy Hospital, University of Helsinki, Finland. kaarina.kukkonen@hus.fi
Savilahti E
No affiliation info available
Haahtela T
No affiliation info available
Juntunen-Backman K
No affiliation info available
Korpela R
No affiliation info available
Poussa T
No affiliation info available
Tuure T
No affiliation info available
Kuitunen M
No affiliation info available

MeSH

BifidobacteriumChild, PreschoolDouble-Blind MethodEczemaFecesFemaleHumansHypersensitivityInfantInfant, NewbornLactobacillus rhamnosusMaleOligosaccharidesPregnancyProbioticsPropionibacterium

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17208601

Citation

Kukkonen, Kaarina, et al. "Probiotics and Prebiotic Galacto-oligosaccharides in the Prevention of Allergic Diseases: a Randomized, Double-blind, Placebo-controlled Trial." The Journal of Allergy and Clinical Immunology, vol. 119, no. 1, 2007, pp. 192-8.
Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007;119(1):192-8.
Kukkonen, K., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., Tuure, T., & Kuitunen, M. (2007). Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. The Journal of Allergy and Clinical Immunology, 119(1), 192-8.
Kukkonen K, et al. Probiotics and Prebiotic Galacto-oligosaccharides in the Prevention of Allergic Diseases: a Randomized, Double-blind, Placebo-controlled Trial. J Allergy Clin Immunol. 2007;119(1):192-8. PubMed PMID: 17208601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. AU - Kukkonen,Kaarina, AU - Savilahti,Erkki, AU - Haahtela,Tari, AU - Juntunen-Backman,Kaisu, AU - Korpela,Riitta, AU - Poussa,Tuija, AU - Tuure,Tuula, AU - Kuitunen,Mikael, Y1 - 2006/10/23/ PY - 2006/06/09/received PY - 2006/09/07/revised PY - 2006/09/11/accepted PY - 2007/1/9/pubmed PY - 2007/3/14/medline PY - 2007/1/9/entrez SP - 192 EP - 8 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 119 IS - 1 N2 - BACKGROUND: The increase in allergic diseases is attributed to a relative lack of microbial stimulation of the infantile gut immune system. Probiotics, live health-promoting microbes, might offer such stimulation. OBJECTIVE: We studied the effect of a mixture of 4 probiotic bacterial strains along with prebiotic galacto-oligosaccharides in preventing allergic diseases. METHODS: We randomized 1223 pregnant women carrying high-risk children to use a probiotic preparation or a placebo for 2 to 4 weeks before delivery. Their infants received the same probiotics plus galacto-oligosaccharides (n = 461) or a placebo (n = 464) for 6 months. At 2 years, we evaluated the cumulative incidence of allergic diseases (food allergy, eczema, asthma, and allergic rhinitis) and IgE sensitization (positive skin prick test response or serum antigen-specific IgE level >0.7 kU/L). Fecal bacteria were analyzed during treatment and at age 2 years. RESULTS: Probiotic treatment compared with placebo showed no effect on the cumulative incidence of allergic diseases but tended to reduce IgE-associated (atopic) diseases (odds ratio [OR], 0.71; 95% CI, 0.50-1.00; P = .052). Probiotic treatment reduced eczema (OR, 0.74; 95% CI, 0.55-0.98; P = .035) and atopic eczema (OR, 0.66; 95% CI, 0.46-0.95; P = .025). Lactobacilli and bifidobacteria more frequently (P < .001) colonized the guts of supplemented infants. CONCLUSION: Probiotic treatment showed no effect on the incidence of all allergic diseases by age 2 years but significantly prevented eczema and especially atopic eczema. The results suggest an inverse association between atopic diseases and colonization of the gut by probiotics. CLINICAL IMPLICATIONS: The prevention of atopic eczema in high-risk infants is possible by modulating the infant's gut microbiota with probiotics and prebiotics. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/17208601/Probiotics_and_prebiotic_galacto_oligosaccharides_in_the_prevention_of_allergic_diseases:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(06)01908-7 DB - PRIME DP - Unbound Medicine ER -